ClinicalTrials.gg
CompletedNCT00520936Updated Feb 25, 2011Results posted

A Study of Pemetrexed in Children With Recurrent Cancer

A Phase 2 interventional study of pemetrexed in Osteosarcoma, Medulloblastoma and Sarcoma, Ewing's, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2011-02-25.

Primary conditionSarcoma, EwingRegistry: OsteosarcomaReclassifiedWhy we changed it
Registry
Osteosarcoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sarcoma, Ewing
Why
  1. The study's listed conditions name Sarcoma, Ewing, a narrower term within Osteosarcoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
Up to 22 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 167 studies in Sarcoma, Ewing with a site in United States — 39 open to participants now, 61 under way, 1 of them phase 3. Sarcoma, Ewing · United States.

Enrollment
40th of 155
72 · median 30
Started
2007
with 4 others
Phase 2
47 of 167
5 open now
Registered
21st of 167
by date
Lead sponsor
4 of 167
Eli Lilly and Company

Among the 167 studies in Sarcoma, Ewing with a site in United States, this one is the 40th largest by enrollment of the 155 interventional ones that give a count, is one of 5 that started in 2007, is one of 47 in phase 2, and was the 21st registered.

Sarcoma, Ewing

250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.

Browse Sarcoma, Ewing studies →

Open to participants now

39 of the 167 studies in Sarcoma, Ewing with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.

This study: Up to 22 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Sarcoma, Ewing with a site in United States, or all of them as a file.
02

Study summary

To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.

03

Conditions studied

  • Osteosarcoma
  • Medulloblastoma
  • Sarcoma, Ewing's
  • Neuroblastoma (Measurable Disease)
  • Neuroblastoma (Metaiodobenzylguanidine
  • Positive Evaluable)
  • Rhabdomyosarcoma
  • Ependymoma
  • Non-brainstem High-grade Glioma
04

In context

Sarcoma, Ewing Reclassified

250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.

This study's enrollment of 72 is above the median of 36 across 204 interventional studies indexed under Sarcoma, Ewing.

Browse Sarcoma, Ewing studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Sarcoma, Ewing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteosarcoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Up to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have osteosarcoma, Ewing's sarcoma, medulloblastoma, neuroblastoma, rhabdomyosarcoma, ependymoma or high-grade non-brainstem glioma
  • (ECOG) performance 0,1,2
  • Adequate renal, liver and bone marrow function
  • Patient's current disease state must be one with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life

Exclusion criteria

Exclusion Criteria:

  • Growth factors that support or white cell number or function must not have been administered within the last 7 days prior to enrollment (14 days if Neulasta)
  • Patients with central nervous system (CNS) tumors who have not been on a stable or decreasing dose of dexamethasone or other for 7 days prior to enrollment
  • Patients with uncontrolled infection
  • Patients who have received pemetrexed previously
  • Patients with pleural effusions or ascites
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Drug: pemetrexed

Interventions

  • 1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles

    Also known as: LY 231514, Alimta

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Tumor Response (Response Rate)

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response = disappearance of all target lesions. Partial Response = 30% decrease in sum of longest diameter of target lesions. Response rate (percent \[%\])= (number of participants with complete response (CR) or partial response (PR) in stratum/number of participants in stratum)\*100.

    Time frame: baseline to measured progressive disease (up to 1 year)

Secondary outcomes

  1. Number of Patients With Adverse Events, Discontinuations, or Deaths Possibly Due to Study Drug

    AdEERS= Adverse Event Expedited Reporting System; AE = adverse event. Patients may be counted in more than 1 category. Includes events that were considered possibly related to study drug (PRSD) as judged by the investigator.

    Time frame: every cycle (up to 2 years and 7 months)

  2. Pharmacogenomics - Measure the Response of Genes Related to Toxicity

    The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here. Results of this optional research may be reported in the future by the Children's Oncology Group in the peer-reviewed literature.

    Time frame: baseline

08

Results

Posted Feb 23, 2011

Participant flow

Participant flow — Overall Study
MilestoneOsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade Glioma
Started1011956101110
Completed1077551079
Not completed04201041
Withdrew: Physician decision02100000
Withdrew: Withdrawal by subject00000001
Withdrew: Toxicity requiring removal from study01000020
Withdrew: Death00000010
Withdrew: Protocol violation01101010

Outcome measures

PrimaryPercentage of Participants With Overall Tumor Response (Response Rate)

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response = disappearance of all target lesions. Partial Response = 30% decrease in sum of longest diameter of target lesions. Response rate (percent \[%\])= (number of participants with complete response (CR) or partial response (PR) in stratum/number of participants in stratum)\*100.

Time frame:
baseline to measured progressive disease (up to 1 year)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Overall Tumor Response (Response Rate)
Percentage of ParticipantsOsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade Glioma
Percentage of Participants With Overall Tumor Response (Response Rate)00000000
SecondaryNumber of Patients With Adverse Events, Discontinuations, or Deaths Possibly Due to Study Drug

AdEERS= Adverse Event Expedited Reporting System; AE = adverse event. Patients may be counted in more than 1 category. Includes events that were considered possibly related to study drug (PRSD) as judged by the investigator.

Time frame:
every cycle (up to 2 years and 7 months)
Reported as:
Number · Participants
Number of Patients With Adverse Events, Discontinuations, or Deaths Possibly Due to Study Drug
ParticipantsOsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade Glioma
>=1 AdEERs possibly related to study drug32023222
Discontinued due to AE possibly related to drug01000020
Died on therapy possibly related to study drug00000000
Died within 31 days of last dose of drug PRSD00000000
SecondaryPharmacogenomics - Measure the Response of Genes Related to Toxicity

The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here. Results of this optional research may be reported in the future by the Children's Oncology Group in the peer-reviewed literature.

Time frame:
baseline
Reported as:
Number · Correlation coefficient

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—21/72 (29.2%)10/72 (13.9%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPemetrexed
Febrile neutropeniaBlood and lymphatic system disorders4/72
Infection with normal ANC or Grade 1Blood and lymphatic system disorders4/72
LeukocytesBlood and lymphatic system disorders3/72
LymphopeniaBlood and lymphatic system disorders3/72
Neutrophils/granulocytesBlood and lymphatic system disorders3/72
Phosphate, serum-lowMetabolism and nutrition disorders3/72
Death not associated with CTCAE termRespiratory, thoracic and mediastinal disorders3/72
InfectionBlood and lymphatic system disorders2/72
PlateletsBlood and lymphatic system disorders2/72
NauseaGastrointestinal disorders2/72
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPemetrexed
Infection with normal ANC or Grade 1Blood and lymphatic system disorders2/72
FeverGeneral disorders2/72
SeizureNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/72
HypoxiaRespiratory, thoracic and mediastinal disorders2/72
Dermatology/Skin - OtherCardiac disorders1/72
Pulmonary/Upper Respiratory - OtherCardiac disorders1/72
Thrombosis/thrombus/embolismCardiac disorders1/72
Sodium, serum-lowCongenital, familial and genetic disorders1/72
DiarrheaGastrointestinal disorders1/72
Hemorrhage, GI: RectumGastrointestinal disorders1/72

Baseline characteristics

Age Continuous
Age Continuous(years)OsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade GliomaTotal
Mean14.94 ± 4.2818.24 ± 3.358.74 ± 4.966.23 ± 2.989.62 ± 5.388.42 ± 4.5912.00 ± 7.1312.75 ± 5.1511.96 ± 5.97
Sex: Female, Male
Sex: Female, Male(Participants)OsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade GliomaTotal
Female4861134532
Male6334577540
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade GliomaTotal
American Indian or Alaska Native002000002
Asian010000012
Black or African American4002113314
White4872498648
Other110100003
Unknown110010003
Region of Enrollment
Region of Enrollment(participants)OsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade GliomaTotal
United States778559101061
Canada3410111011
Karnofsky Performance Score
Karnofsky Performance Score(Participants)OsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade GliomaTotal
100020001003
90330010119
80010000012
70010000102
50100000102
Missing6495598854
Lansky Play Score
Lansky Play Score(Participants)OsteosarcomaEwing's Sarcoma/Peripheral Primitive Neuroectodermal TumorsRhabdomyosarcomaNeuroblastoma (Measureable Disease)Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable)EpendymomaMedulloblastoma/Supratentorial Primitive Neuroectodermal TumorNon-Brainstem High-Grade GliomaTotal
1001134222318
901331123418
802020232011
70000001012
60101001104
50100000001
Missing4700113218
09

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arcadia, California 91066, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2007
First posted
Aug 27, 2007
Start
Sep 2007
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Feb 23, 2011
Last update
Feb 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00520936
First posted
Aug 27, 2007
Start date
Sep 2007
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Feb 23, 2011
Last update
Feb 25, 2011

Study contacts

1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion